Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929

A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene

Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751

The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting

Merad, M., Sathe, P., Helft, J., Miller, J., & Mortha, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074950 · Cited by 2,309

Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity

Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081

Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma

Roberts, E. W., Broz, M. L., Binnewies, M., Headley, M. B., Nelson, A. E., Wolf, D. M., Kaisho, T., Bogunovic, D., Bhardwaj, N., & Krummel, M. F. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.003 · Cited by 1,030

IL-23 promotes tumour incidence and growth

Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018

Modified mRNA vaccines protect against zika virus infection

Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., & Ryan, J. L. (1997) · PubMed · Cited by 820

A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates

Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.010 · Cited by 820

mRNA Vaccines in Cancer Immunotherapy: Recent Advances, Clinical Translation, and Future Perspectives

Pati, S. S., Dhal, S., Pattnaik, R., Tripathy, S., & Kumar, S. (2025) · Current Medical Science · doi:10.1007/s11596-025-00112-5 · Cited by 11

Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists

Cirella, A., Bolaños, E., Luri‐Rey, C., Trani, C. A. D., Olivera, I., Gomis, G., Glez‐Vaz, J., Pinci, B., Garasa, S., Sánchez‐Gregorio, S., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.07.026 · Cited by 10

Advances and challenges in cancer immunotherapy: Strategies for personalized treatment

Azmal, M., Miah, M. M., Prima, F. S., Paul, J. K., Haque, A. S. N. B., & Ghosh, A. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152345 · Cited by 12

Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response

Wang, Q., Liu, Y., Wang, J., & Wang, H. (2023) · ChemMedChem · doi:10.1002/cmdc.202200673 · Cited by 9

Biomaterial-Mediated Genetic Reprogramming of Merkel Cell Carcinoma and Melanoma Leads to Targeted Cancer Cell Killing In Vitro and In Vivo

Luly, K. M., Green, J. J., Sunshine, J. C., & Tzeng, S. Y. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00885 · Cited by 10

In Situ Reprogramming of Tumors for Activating the OX40/OX40 Ligand Checkpoint Pathway and Boosting Antitumor Immunity

Gao, Y., Zhao, J., Huang, Z., Zhao, H., Guo, Z., Ma, S., Tang, X., Song, W., & Chen, X. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c01637 · Cited by 9

Long‐Term Storage Stable Vesicle‐Like Nanoparticles of Lipid and Polymer for siRNA and mRNA‐Mediated Cancer Immunotherapy

Chen, C., Zhang, Y., Cao, Z., Li, D., Zhu, Y., Jing, H., Li, Y., Li, F., Xu, C., Yang, X., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202406101 · Cited by 8

Emerging Strategies of Cell and Gene Therapy Targeting Tumor Immune Microenvironment

Wang, R., Duan, X., Li, J., Zhang, C., & Shen, L. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-4308 · Cited by 10

Beta-blockers prolong response to androgen deprivation therapy in prostate cancer through modulation of the neuro-immuno-oncology axis

Thulin, M. H., Ramberg, H., Nielsen, H. K., Grytli, H. H., Sivanesan, S., Pandya, A. D., Seip, K., Andressen, K. W., Linder, A., Øijordsbakken, M., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06644-7 · Cited by 12

A material toolbox for engineering targeted lipid nanoparticles for RNA therapies

Yoo, S., Ang, M. J. Y., Murray, A. M., & Mitchell, M. J. (2026) · Materials Today · doi:10.1016/j.mattod.2025.12.034 · Cited by 9

Lipid nanoparticles delivering constitutively active STING mRNA as a novel anti-cancer therapeutic approachPreprint

Liu, W., Alameh, M., Yang, J. F., Xu, J. R., Lin, P. J. C., Tam, Y. K., Weissman, D., & You, J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.08.475499 · Cited by 8

Oncolytic virus encoding 4-1BBL and IL15 enhances the efficacy of tumor-infiltrating lymphocyte adoptive therapy in HCC

Ye, K., Yan, Y.-F., Su, R., Dai, Q., Qiao, K., Cao, Y., Xu, J. C., Yan, L., Huo, Z., Liu, W., et al. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00853-w · Cited by 7

In Situ Tumor Vaccination Using Lipid Nanoparticles to Deliver Interferon-β mRNA Cargo

Kimura, K., Aicher, A., Niemeyer, E., Areesawangkit, P., Tilsed, C. M., Fong, K. P., Papp, T. E., Albelda, S. Μ., Parhiz, H., & Predina, J. D. (2025) · Vaccines · doi:10.3390/vaccines13020178 · Cited by 7

Expanding global access to mRNA vaccines

Eshaghi, B., Langer, R., & Jaklenec, A. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-026-00424-8 · Cited by 8

Drug Survival and Clinical Course of Patients with Cancer Treated with Biologic Therapy for Psoriasis

Macagno, N., Mastorino, L., Ortoncelli, M., Borriello, S., Astrua, C., Verrone, A., Stroppiana, E., Dapavo, P., Siliquini, N., Ribero, S., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216546 · Cited by 7

In Situ Delivery of Gasdermin E mRNA Promotes Antitumor Immunity via Creatine-Elicited Type I Interferon Signaling in Monocytes

Li, H., Lu, J., Tan, S., Jiang, T., He, X., Qiao, W., Hu, C., Dalangood, S., Lin, J., & Gui, J. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0834 · Cited by 8

Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy

Rehman, M., Qaiser, A., Khan, H. S., Manzoor, S., & Ashraf, J. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01442-9 · Cited by 6

Bifunctional chemokine-nanobody fusion protein enhances neutrophil recruitment to impede Acanthamoeba immune evasion

Wei, Z., Yuan, J., Chen, Q., Pang, J., Shi, Q., Peng, B., Wei, M., Wei, Y., Zhang, Z., Lu, X., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105685 · Cited by 6

Biocompatible lipid nanovehicles for preventive and therapeutic vaccine development

Jia, Y., Zhou, Z., Jiramonai, L., Chen, J., Hua, Q., Zhu, M., Zhang, J., & Liang, X. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216718 · Cited by 7

Tertiary lymphoid structures in esophageal cancer: a novel target for immunotherapy

Zhai, K., Ma, Y., Gao, X., Ru, K., & Zhao, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1543322 · Cited by 6

Intratumoral immunotherapy prior to cancer surgery, a promising therapeutic approach

Silihe, K. K., & Fiering, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1545000 · Cited by 6

Nanoparticle delivery of VEGF-B mRNA promotes T cell infiltration within tumor and triggers robust antitumor immunity

Zhang, G., Tu, J., Zhang, Y., He, J., Peng, G., Fan, Q., Zhang, Y., Zhang, M., Tan, H., Xu, Y., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102620 · Cited by 6

In Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical Translation

Shi, Y., Hou, Y., Mabrouk, M. T., Yu, C., & Yang, Y. (2025) · Advanced Science · doi:10.1002/advs.202509836 · Cited by 7

Advances in lipid nanoparticles delivering genetic medicines for solid cancers

Yang, F., & Scott, T. A. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102838 · Cited by 10

Beyond the Sequence: Chemical and Topological Design and Innovations in mRNA Therapeutics

Liu, D., Chen, H., Pan, A., & Wang, X. (2026) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00347 · Cited by 7

The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy

Berraondo, P., Gomis, G., & Melero, I. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.015 · Cited by 6

Integrating system biology and intratumor gene therapy by trans-complementing the appropriate co-stimulatory molecule as payload in oncolytic herpes virus

Finizio, A., Pagano, P., Napolano, A., Froechlich, G., Infante, L., Chiara, A. D., Amiranda, S., Vitiello, E., Totaro, S., Capasso, C., et al. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00790-8 · Cited by 6

Combining mRNA with PBS and calcium ions improves the efficiency of the transfection of mRNA into tumors

Ohta, N., Matsuzaki, T., Nakai, M., Tabata, Y., & Nimura, K. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102273 · Cited by 6

Intratumoral delivery of mRNA encoding the endogenous TLR2/6 agonist UNE-C1 induces immunogenic cell death and enhances antitumor activity

Kim, U., Hwang, S., Cho, S., Kim, H. Y., Ban, H., Park, J., Mun, J., Kim, N., Suh, J. H., Choi, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1454504 · Cited by 6

Intraperitoneal administration of mRNA encoding interleukin-12 for immunotherapy in peritoneal carcinomatosis

Arrizabalaga, L., Trani, C. A. D., Fernández-Sendin, M., Bella, Á., Russo-Cabrera, J. S., Gomar, C., Ardaiz, N., Belsúe, V., González-Gomariz, J., Zalba, S., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03196-2 · Cited by 6

Enhanced Antitumor Immunity Through T Cell Activation with Optimized Tandem Double-OX40L mRNAs

Deng, Z., Tian, Y., Wang, J., Xu, Y., Liu, Z., Xiao, Z., Wang, Z., Hu, M., Liu, R., & Yang, P. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s479434 · Cited by 7

Analysis of the Immunostimulatory Effects of Cytokine-Expressing Internal Ribosome Entry Site–Based RNA Adjuvants and Their Applications

Lee, Y., Bang, Y., Yoo, S., Park, S., Park, H., Kwak, H. W., Bae, S., Park, H.-J., Kim, J., Youn, S. B., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad392 · Cited by 6

bioPROTACs establish RAS as a degradable target and provide novel RAS biology insightsPreprint

Lim, S., Khoo, R., Juang, Y.-C. A., Gopal, P., Zhang, H., Yeo, C., Peh, K. M., Teo, J., Ng, S., Henry, B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.26.174565 · Cited by 6

Lipid Nanoparticle–Encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ plus Durvalumab Induces an Immunostimulatory Effect within the Tumor Microenvironment in Patients with Advanced Solid Tumors

Sweis, R. F., Long, G. V., DAUD, A. I., Stemmer, S. M., Jimeno, A., Perets, R., Kummar, S., Patel, M. R., Khattak, A., Abadier, M., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4643 · Cited by 5

An Engineered Influenza a Virus Expressing the Co-Stimulator OX40L as an Oncolytic Agent Against Hepatocellular Carcinoma

Hao, Y., Lei, G., Deng, Z., Sun, F., Tian, Y., Cheng, J., Yu, H., Li, C., Bai, C., Zhang, S., et al. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s410703 · Cited by 5

Therapeutic Immunomodulation of Tumor-Lymphatic Crosstalk via Intratumoral Immunotherapy

Lucas, S. N., & Thomas, S. N. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00692 · Cited by 5

A drug delivery perspective on intratumoral-immunotherapy in renal cell carcinoma

Meng, W. S., Salgia, N., Pham, N. B., Velankar, K. Y., & Pal, S. K. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.03.018 · Cited by 5

Drug loaded nanomaterials for hematological malignancies diagnosis and enhanced targeted therapy

Samal, P., & Begum, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85725-3.00016-7 · Cited by 5

In Situ Synthesis of a Tumor-Microenvironment-Responsive Chemotherapy Drug

Wang, X., Oyane, A., Inose, T., & Nakamura, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041316 · Cited by 5

Advancing cancer immunotherapy through emerging intratumoral delivery and biomedical imaging technologies

Choi, E.-S., Bagley, A. F., Haque, S., Winters, C., & Sun, C. (2024) · Materials Today Advances · doi:10.1016/j.mtadv.2024.100539 · Cited by 4

Recent Advances in mRNA Therapeutic Cancer Vaccines

Laflin, A. D., Pan, J., You, M., & Jiang, S. (2026) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110824-034150 · Cited by 4

Gene-Immune Therapy of Cancer: Approaches and Problems

Алексеенко, И. В., Pleshkan, V. V., Kuzmich, A. I., Kondratieva, S. A., & Sverdlov, E. D. (2022) · Russian Journal of Genetics · doi:10.1134/s1022795422040020 · Cited by 4

The diagnostic value of interleukin-36 cytokines in pleural effusions of varying etiologies

Song, X., Guo, L., Zhang, Q., Chen, W., Fan, W., Lv, C., Tang, P., Dong, Z., Ye, X., & Ding, Q. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117533 · Cited by 4

IL-36 antagonism blunts the proliferation and migration of oral squamous cell carcinoma cells

Li, Z., Zhang, X.-X., Li, K., Li, F., Kou, J., Wang, Y., Wei, X., Sun, Y., Jing, Y., Song, Y., et al. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111096 · Cited by 4

Intratumoral expression of IL-12 from lentiviral or RNA vectors acts synergistically with TLR4 agonist (GLA) to generate anti-tumor immunological memory

Leleux, J. A., Albershardt, T. C., Reeves, R. S., James, R. D., Krull, J. E., Parsons, A. J., ter Meulen, J., & Berglund, P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259301 · Cited by 4

Administration of lipid nanoparticle-encapsulated mRNA encoding CCR7, CXCL16 and GITRL effectively mobilizes antitumor T cell immunity

Chen, J., Cen, Q., Hu, R., Qiu, Y., Zhang, H., Wang, H., Hu, Y., Xie, X., & Li, Y. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144766 · Cited by 3

Artificial Transmembrane Oligopeptide‐Integrated Interferon mRNA with Monoclonal Antibody to Improve Specificity and Efficacy of Cancer Immunotherapy

Yan, Y., Luo, Z., Hu, X., Ou, M., Huang, M., Ni, X. F., Chen, H., & Ding, Y. (2025) · Advanced Materials · doi:10.1002/adma.202503139 · Cited by 3

Microenvironment of Solid Tumors

Korneenko, T. V., Pestov, N. B., Shakhparonov, M. I., & Barlev, N. A. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl36940 · Cited by 3

Development of mRNA Cancer Vaccines: Delivery Strategies and Immunogenicity Optimization

Ali, A. (2025) · Current Medical Science · doi:10.1007/s11596-025-00127-y · Cited by 4

Convergence of mRNA technology and chimeric antigen receptor therapy: targeted technology optimizing targeted therapy

Chen, H., Zhang, J., Huang, J., Wu, Z., Tang, L., Tian, Y., Gao, S., Huang, S., Cao, J., Chen, J., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07470-7 · Cited by 3

Triplet RNA Lipid Nanoparticles for Locoregional Cancer Immunotherapy

Walters, A. A., Qin, Y., Saleh, A. F., Cheung, C. C. L., Lyu, Q., Zhu, Z., Gafar, H. A. M., Wang, J. T.-W., & Al‐Jamal, K. T. (2025) · Small Science · doi:10.1002/smsc.202500506 · Cited by 3

Restoring Tumor Suppression Activity: Mimicking Molecules (TargomiRs and MRX34) and Synthetic RNAs (MTL-CEBPA)

Naik, K. A. P., Kethavath, S. N., Rosangzula, K., Saikrishna, J., Sangeetha, R., Patlolla, R. R., Chandgude, A. H., & Banoth, L. (2026) · Springer eBooks · doi:10.1007/978-981-95-5071-5_12 · Cited by 3

mRNA Vaccines in Melanoma Immunotherapy—A Narrative Review

Plewa, P., Ćmil, M., Lewandowski, F., Poniewierska-Baran, A., & Pawlik, A. (2026) · Cells · doi:10.3390/cells15030298 · Cited by 4

Enhanced efficacy of a next-generation EEEV self-replicating RNA platform for combination cancer immunotherapies

Miyake-Stoner, S. J., Maine, C. J., Chou, A. C., Dailey, G. P., Spasova, D. S., Domingo, C. C., Sparks, J., Picarda, G. G. A., Lyerly, H. K., Crosby, E. J., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.026 · Cited by 3

Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models

Gupta, A., Das, R., Reed, K., Jeon, T., Nguyen, Q. T. C., Rudra, A., Ge, X., Trongjit, S., Vanrobaeys, Y. S., Langer, R., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03115-2 · Cited by 6

Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors

Niu, D., Ma, X., Zhu, J., Sun, L., Zhang, S., Wu, Y., Shan, M., Dai, X., Liao, Y., Liu, D., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102413 · Cited by 3

Nanomedicine Approaches for In Vivo Cancer Immunotherapy

Hofstraat, S. R. J., Anbergen, T., & van der Meel, R. (2023) · Nanomedicine · doi:10.2217/nnm-2023-0230 · Cited by 3

Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses

Albadr, R. J., Sameer, H. N., Athab, Z. H., Adil, M., Yaseen, A., & Allela, O. Q. B. (2025) · Biological Procedures Online · doi:10.1186/s12575-025-00269-2 · Cited by 4

Formulation screening for local delivery of mRNA and photosensitizer to treat superficial tumor

Huang, L., Tang, S., Guo, J., Tu, Y., Li, S., Yang, T., Zhao, D. B., & Wang, C. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107525 · Cited by 2

Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer

Parikh, C. N., DeMarco, K. D., Bhalerao, N., Giwa, H. K., Kane, G. I., Dinnell, R. W., Ma, B., Mori, H., Brassil, M. L., Murphy, K. C., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74574-z · Cited by 3

A comprehensive analysis of the use of nucleoside analogues in RNA therapeutics

Kukushkina-Zvezdova, A. A., Zherebtsova, A. A., Telegina, D. V., Skvortsov, I. A., Ivanov, R. A., & Reshetnikov, V. V. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08083-4 · Cited by 3

Intratumoral Delivery of Genetically Engineered Anti-IL-6 Trans-signaling Therapeutics

Bento, R., Scheller, J., & Parekkadan, B. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01230-6 · Cited by 2

Enhanced antitumor efficacy of STING agonist MSA-2 by lipid nanoparticles delivering circular IL-23 mRNA and platinum-modified MSA-2 combination

Tian, H., Li, Y., Li, W., Zhang, M., Wang, G., Zhou, P., Song, G., & Li, W. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101446 · Cited by 3

A ready-to-use RNA delivery platform modulated by metal ions

Qin, Z., Jiang, Y., Tao, P., Liu, H., Han, Z., Ding, X., Zhao, R., Lu, Y., Zhang, L., Chen, X., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.160170 · Cited by 2

Precision Targeting of Myeloid Cells via Peptide Dendrimer‐Lipid Nanocarriers: A Novel Platform for Potent Cancer Immunotherapies

Billing, L., Martin, L., Henser‐Brownhill, T., Samangouei, P., Leach, A., Knight, P., Apostolidou, M., Ladak, A., Nagel, B., & Kwok, A. (2025) · Advanced Science · doi:10.1002/advs.202514417 · Cited by 3

Floxed Il1rl2 Locus with mCherry Reporter Element Reveals Distinct Expression Patterns of the IL-36 Receptor in Barrier Tissues

Tongmuang, N., Cai, K. Q., An, J., Novy, M., & Jensen, L. E. (2024) · Cells · doi:10.3390/cells13090787 · Cited by 2

Advances in Therapeutic Targeting of the Tumor Necrosis Factor Receptor Superfamily Members for Cancer Immunotherapy

Vlaming, M. R., He, Y. Z., & Bremer, E. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_196-1 · Cited by 1

Natural and Engineered Cytokines as Cancer Therapeutics

O'Neal, P., Bharathkar, S. K., McCue, A. C., & Spangler, J. B. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070524-040306 · Cited by 1

Multi-seed searching algorithm for integrated codon optimization of mRNA stability and translational efficiency in vaccine design

Bo, Y., Liu, B., Huang, S., Liu, Y., Deng, L., Zhang, D., & Zhang, J. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag047 · Cited by 1

Identification of the Inflammatory Cytokine Tumor Necrosis Factor Superfamily 4 as an Oncogenic Driver and Potential Druggable Target in Hepatocellular Carcinoma

Hosoda, K., MASUDA, T., Saito, H., Koike, K., Ando, Y., Abe, T., Hashimoto, M., Nakano, Y., Dairaku, K., Hirose, K., et al. (2026) · Hepatology Research · doi:10.1111/hepr.70135 · Cited by 1

2-arm-PEG-Oligocations Transiently Shield the Liver Sinusoids to Mitigate Off-Target Hepatic Expression of mRNA Lipid Nanoparticles

Dirisala, A., Chatterjee, B., Nguyen, L. B. T., Toh, K., Matsui-Masai, M., Abbasi, S., Liu, X., Tockary, T. A., Qiao, N., Ishikawa, J., et al. (2026) · ACS Nano · doi:10.1021/acsnano.6c08403 · Cited by 1

A novel mRNA-based multi-cytokine strategy to reprogram the peritoneal tumor microenvironment in ovarian cancer

Lee, Y., Lee, J., Lee, Y., Yoon, H., Bae, S., Yoon, S., Lee, S., Roh, G., Cho, Y., Cho, S., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04543-7 · Cited by 1

mRNA Lipid Nanoparticles for Cell Engineering in Vivo and in Vitro: Current Applications and Future Directions

Li, L., Wang, M., Ye, X., Liu, Z., Duan, Y., Chen, X., Ouyang, Y., Wu, Q., Sun, M., & Xie, T. (2026) · MedComm · doi:10.1002/mco2.70700 · Cited by 1

New approach methodologies (NAMs) for preclinical and translational evaluation of mRNA–lipid nanoparticle (LNP) therapeutics

Zhou, J., Li, N., Liu, R., Kabanov, A. V., Polacheck, W. J., Nguyen, J., & Cao, Y. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115157 · Cited by 3

Neue Strategien für die onkologische Therapie: Interleukine im Fokus

Jobst, J., & Kobold, S. (2021) · Deutsches Ärzteblatt · doi:10.3238/personko.2021.11.26.07 · Cited by 1

Intratumoral Manipulation of the Immune Microenvironment of Solid Tumors

Mao, L., Xu, K., Jin, T., Yan, W., & Fang, R. H. (2025) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00063 · Cited by 1

External stimuli-responsive nanomedicine for cancer immunotherapy

Niu, L., Jang, E., Chin, A. L., & Tong, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822425-0.00026-9 · Cited by 1

1069 IL-12 mRNA monotherapy is effective in murine tumors resistant to checkpoint inhibition

Santha, S., Lakshmipathi, J., Li, M., Qian, Y., Luheshi, N., Politi, K. A., Bosenberg, M., Eyles, J. E., & Muthusamy, V. (2023) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2023-sitc2023.1069 · Cited by 1

Classes, Modes of Action and Selection of New Modalities in Drug Discovery

Valeur, E. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160691-00277

Cancer Nanomedicine: Strategies to Enhance Tumor Delivery and Immunotherapy

Li, Y., & Luo, M. (2020) · Journal of Nanotechnology and Nanomaterials · doi:10.33696/nanotechnol.1.011

Engineered devices for tumor microenvironment immune modulation

Cryer, A. M., & Artzi, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90949-5.00005-x

Nucleic acid-based immune checkpoint blockade: Progress and potential

Walters, A. A., Dhadwar, B., & Al‐Jamal, K. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00011-7

Capitalizing on the messenger: Intra-tumoral delivery of RNA with a systemic effect

Ott, P. A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.004

The Impact of Myeloid-Mediated Co-Stimulation and Immunosuppression on the Anti-Tumor Efficacy of Adoptive T cell Therapy

Innamarato, P. (2020) · Digital Commons - University of South Florida (University of South Florida)

"Venceréis pero no convencéreis": encontronazo en Salamanca

Florencio, R. N. (2014) · La Aventura de la historia

Data from Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment

Hewitt, S. L., Bailey, D., Zielinski, J., Apte, A., Musenge, F. M., Karp, R., Burke, S., Garçon, F., Mishra, A., Gurumurthy, S., et al. (2023) · doi:10.1158/1078-0432.c.6529685

The Future of Chimeric Antigen Receptor T Cell Therapy

Smith, E. L. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.06.005

New Therapeutic Chemical Modalities: Compositions, Modes-of-action, and Drug Discovery

Valeur, E. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00911

RNA therapeutics for diarrhea

Nguyen, D. H., Uddin, M. J., Al‐Tawfiq, J. A., Memish, Z. A., & Chu, D. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.004

mRNA-based cancer therapeutics

Hillery, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28934-7.00006-6

Lipid nanoparticles as a tool to dissect dendritic cell maturation pathwaysPreprint

Janssens, S., Rennen, S., Bosteels, V., Nolf, C. D., Lil, K. V., Maréchal, S., Vetters, J., Velde, E. V. D., Fayazpour, F., Roelandt, R., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5461735/v1

Cancer Vaccines Based on mRNA: Hype or Hope?

de Mey, W., Autaers, D., Bertazzon, G., Esprit, A., Aragon, M. M., Franceschini, L., & Breckpot, K. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch13

Advances in Therapeutic Targeting of the Tumor Necrosis Factor Receptor Superfamily Members for Cancer Immunotherapy

Vlaming, M. R., He, Y. Z., & Bremer, E. (2025) · Springer eBooks · doi:10.1007/978-3-032-00767-4_196

mRNA-based vaccines: Rational antigen design, delivery optimization, and immune modulation

Liu, S., Shi, H., Dai, D., Tian, T., Duan, X., Sun, J., Xu, W., Yin, X., Xie, Y., & Song, X. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.112312

Folate- and aCD47-functionalized lipid nanoparticles efficiently deliver mRNA and remodel pancreatic tumor microenvironment

Parés, M., Martínez-Latorre, J., Candela‐Noguera, V., Soriano‐Teruel, P. M., García‐Fernández, A., Pallaruelo-Santamaría, V., Aznar, E., Martínez‐Máñez, R., & Fillat, C. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118919

mRNA-Based Nanomedicine in Cancer: Pharmacokinetic Innovations, Clinical Pharmacy Practice Integration, and the Future of Personalized Oncology

Ravishankar, S., Bhavya, E., Boopathy, N., Sakthivel, S. R., Sekar, S., Murugathirumal, A., & Nandakumar, K. (2026) · Journal of Bio-X Research · doi:10.34133/jbioxresearch.0076

mRNA Technology Beyond Vaccines: Exploring Potential mRNA-Based Therapies for Autoimmune Diseases

Kharat, M. G., Kulkarni, V. A., Chavan, S. P., Gawali, N. B., & Khandarkar, S. M. (2026) · Asian Journal of Pharmaceutical Research · doi:10.52711/2231-5691.2026.00001

Local Anti-CTLA4 Cancer Immunotherapy From Bench to Bedside

Tselikas, L. (2021) · theses.fr (ABES) · doi:10.70675/7e1fa4d8z5408z419bz9394z19ae17697026

Optimising a mRNA Vaccine platform against HIV-1 : from the in vitro transcription design to envelope protein expression

Linares-Fernández, S. (2021) · theses.fr (ABES) · doi:10.70675/17ec09cezeb11z45f7z8529z7ffbf89d664a

Intratumoral Delivery of mRNA for Cancer Immunotherapy: Progresses, Challenges, and Clinical Translation

Ishikawa, U., Mabrouk, M. T., & Yang, Y. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00166

Abstract 1607: Durable efficacy and anti-cancer immunity following intratumoral administration of messenger RNAs encoding IL-36γ, IL-23 and OX40L

Frederick, J. P., Bai, A., Hewitt, S. L., Karp, R., Zielinski, J. F., Ichikawa, K., Apte, A., Bailey, D., Arnold, K., Farlow, S., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-1607 · Cited by 1

Abstract 1711: Induction of anti-tumor immunity by intratumoral delivery of mRNA encoding cytokines and TNFRSF agonists

Gavigan, J.-A., Shi, C., Lampa, M., Malkova, N. V., Yu, Q., Qu, H., Levit, M. N., Wagenaar, T. R., Hotz, C., & Li, X. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-1711 · Cited by 2

Immune checkpoint blockade combined with IL ‐6 and TGF ‐β inhibition improves the therapeutic outcome of m RNA ‐based immunotherapy

Bialkowski, L., der Jeught, K. V., Bevers, S., Joe, P. T., Renmans, D., Heirman, C., Aerts, J. L., & Thielemans, K. (2018) · International Journal of Cancer · doi:10.1002/ijc.31331 · Cited by 38

Abstract CT210: A Phase I, open-label, multicenter, dose escalation study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral injection alone and in combination with immune checkpoint blockade

Bauer, T. M., Patel, M. R., Jimeno, A., Wang, D., McDermott, J. D., Zacharek, S. J., Randolph, W., Johansen, L. M., Hopson, K., Frederick, J. P., et al. (2019) · Clinical Trials · doi:10.1158/1538-7445.sabcs18-ct210

Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells

Lint, S. V., Renmans, D., Broos, K., Goethals, L., Maenhout, S. K., Benteyn, D., Goyvaerts, C., Four, S. D., der Jeught, K. V., Bialkowski, L., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0163 · Cited by 130